CA2315251A1 - Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides - Google Patents

Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides Download PDF

Info

Publication number
CA2315251A1
CA2315251A1 CA002315251A CA2315251A CA2315251A1 CA 2315251 A1 CA2315251 A1 CA 2315251A1 CA 002315251 A CA002315251 A CA 002315251A CA 2315251 A CA2315251 A CA 2315251A CA 2315251 A1 CA2315251 A1 CA 2315251A1
Authority
CA
Canada
Prior art keywords
ulbp
polypeptide
polypeptides
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002315251A
Other languages
English (en)
French (fr)
Inventor
David John Cosman
Jurgen H. Mullberg
William Cristian Fanslow
Richard J. Armitage
Marek Z. Kubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2315251A1 publication Critical patent/CA2315251A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002315251A 1997-12-17 1998-12-17 Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides Abandoned CA2315251A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6985797P 1997-12-17 1997-12-17
US60/069,857 1997-12-17
US9294698P 1998-07-15 1998-07-15
US60/092,946 1998-07-15
PCT/US1998/027048 WO1999031241A1 (en) 1997-12-17 1998-12-17 Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides

Publications (1)

Publication Number Publication Date
CA2315251A1 true CA2315251A1 (en) 1999-06-24

Family

ID=26750491

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002315251A Abandoned CA2315251A1 (en) 1997-12-17 1998-12-17 Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides

Country Status (12)

Country Link
US (7) US6653447B1 (https=)
EP (1) EP1037991B1 (https=)
JP (1) JP4255211B2 (https=)
AT (1) ATE305510T1 (https=)
AU (1) AU742757C (https=)
CA (1) CA2315251A1 (https=)
DE (1) DE69831754T2 (https=)
DK (1) DK1037991T3 (https=)
ES (1) ES2251120T3 (https=)
IL (2) IL136621A0 (https=)
NZ (1) NZ505500A (https=)
WO (1) WO1999031241A1 (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
SK12572001A3 (sk) * 1999-03-15 2002-03-05 Takeda Chemical Industries, Ltd. Proteín, peptid, protilátka, spôsob výroby a farmaceutický prostriedok
WO2002062997A1 (fr) * 2001-02-05 2002-08-15 Takeda Chemical Industries, Ltd. Nouvelle proteine et son utilisation
US6821522B2 (en) 2001-05-31 2004-11-23 The Regents Of The University Of California Tumor Therapy
US7364890B2 (en) 2001-07-28 2008-04-29 Midwest Research Institute Thermal tolerant avicelase from Acidothermus cellulolyticus
DE60232742D1 (de) * 2001-10-04 2009-08-06 Immunex Corp Ul16-bindungsprotein 4
CA2483343A1 (en) * 2002-04-22 2003-10-30 Fred Hutchinson Cancer Research Center Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
WO2004022706A2 (en) * 2002-09-04 2004-03-18 The Trustees Of The University Of Pennsylvania Immune cell receptor ligand and immune cell receptor
EP1413316A1 (en) * 2002-09-27 2004-04-28 Bruno Robert Bifunctional conjugates or fusion proteins
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
ES2345200T3 (es) * 2003-03-24 2010-09-17 The Scripps Research Institute Vacunas de adn contra el crecimiento tumoral y procedimientos de utilizacion de las mismas.
US7666417B2 (en) * 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
GB0403491D0 (en) * 2004-02-17 2004-03-24 Univ Cambridge Tech Polypeptides, methods and means
US7998481B2 (en) * 2004-04-05 2011-08-16 The Regents Of The University Of California Modulation of NKG2D for treating or preventing solid organ allograft rejection
EP2289534B1 (en) 2004-04-05 2017-08-30 The Regents of The University of California NKG2D antibodies for use in the treatment of rheumatoid arthritis or Crohn's disease
JP5149013B2 (ja) 2004-11-29 2013-02-20 セクエノム，インコーポレイティド メチル化ｄｎａを検出する手段、及び方法
US9249464B2 (en) 2004-11-29 2016-02-02 Sequenom, Inc. Kits and methods for detecting methylated DNA
WO2007002905A1 (en) * 2005-06-29 2007-01-04 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
WO2007143245A2 (en) 2006-06-01 2007-12-13 Midwest Research Institute An l-arabinose fermenting yeast
AU2008219020B2 (en) 2007-02-21 2013-08-22 Vaccinex, Inc. Modulation of NKT cell activity with antigen-loaded CDId molecules
WO2009003145A1 (en) * 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
US9611313B2 (en) 2007-06-26 2017-04-04 University Of Miami Antibody-endostatin fusion protein and its variants
US8070021B2 (en) * 2007-10-31 2011-12-06 Momentive Performance Materials Hydraulic container evacuator and method
CN102325875B (zh) 2009-01-08 2018-04-10 阿尔伯爱因斯坦医学有限公司 具有细胞壁结合神经酰胺类糖脂的细菌疫苗及其应用
US20130101590A1 (en) 2010-04-09 2013-04-25 Heather A. Arnett Btnl9 proteins, nucleic acids, and antibodies and uses thereof
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
WO2013036799A2 (en) * 2011-09-09 2013-03-14 Fred Hutchinson Cancer Research Center Methods and compositions involving nkg2d inhibitors and cancer
CA2848368C (en) 2011-09-13 2023-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
US20130156808A1 (en) * 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
EP2875046B2 (en) 2012-07-19 2025-04-30 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
AU2014296288B2 (en) 2013-07-31 2020-02-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using PTH-related and EGF-related molecules
EP3041863A4 (en) 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
BR112016009465A8 (pt) 2013-10-28 2018-01-30 Univ Pittsburgh Commonwealth Sys Higher Education vetor de hsv oncolítico.
AU2015206603B9 (en) 2014-01-14 2019-07-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
US11117969B2 (en) * 2014-12-05 2021-09-14 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands
CA2963274C (en) 2014-12-05 2024-01-30 Avidbiotics Corp. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
AU2016343978A1 (en) 2015-10-29 2018-05-17 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids
KR20180136435A (ko) 2016-01-27 2018-12-24 온코루스, 인크. 종양 살상형 바이러스 벡터 및 그의 용도
CN109475613B (zh) 2016-06-14 2024-02-20 匹兹堡大学-属高等教育联邦体系 使癌细胞对胞毒免疫细胞攻击敏感的nkg2d活化配体蛋白表达
AU2017290828A1 (en) 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
MX2019007406A (es) 2016-12-21 2019-12-16 Creatus Biosciences Inc Especie de metschnikowia productora de xilitol.
CA3047840A1 (en) 2016-12-21 2018-06-28 Creatus Biosciences Inc. Method and organism expressing metschnikowia xylose transporters for increased xylose uptake
CA3056011A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
US11612625B2 (en) 2017-07-26 2023-03-28 Oncorus, Inc. Oncolytic viral vectors and uses thereof
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
JOP20200234A1 (ar) 2018-03-27 2020-09-15 Xyphos Biosciences Inc نطاقات a1-a2 معدلة لمركبات ترابطية nkg2d غير طبيعية ترتبط بمستقبلات nkg2d غير طبيعية.
WO2020051013A2 (en) * 2018-08-24 2020-03-12 The Trustees Of Columbia University In The City Of New York Anti-cd33 and nkg2d ligand chimeras for treatment of myeloid malignancies
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
KR20230087539A (ko) 2020-10-15 2023-06-16 암젠 인크 항체 생산 방법에서의 상대적인 비결합 글리칸
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
US20250076309A1 (en) 2021-10-05 2025-03-06 Amgen Inc. Fc-gamma receptor ii binding and glycan content
EP4479080A1 (en) 2022-02-16 2024-12-25 Dana-Farber Cancer Institute, Inc. Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
USRE38824E1 (en) * 1986-08-04 2005-10-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies against human herpes virus-6(HHV-6) and method of use
US5834229A (en) * 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5464771A (en) * 1994-04-29 1995-11-07 The United States Of America As Represented By The Secretary Of Agriculture Biologically pure culture of Actinomyces viscosus strain used for the bioremediation of chlorinated hydrocarbons
AU2304097A (en) * 1996-04-05 1997-10-29 Kieta Holding S.A. Compositions and methods relating to drug discovery and detection and treatment of gastrointestinal diseases
US5912415A (en) * 1996-05-16 1999-06-15 Regents Of The University Of Minnesota Arabidopsis spindly gene, methods of identification and use
US20030068623A1 (en) * 1997-06-16 2003-04-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Also Published As

Publication number Publication date
US20040235058A1 (en) 2004-11-25
US6653447B1 (en) 2003-11-25
AU742757B2 (en) 2002-01-10
NZ505500A (en) 2002-12-20
EP1037991A1 (en) 2000-09-27
AU2004599A (en) 1999-07-05
JP4255211B2 (ja) 2009-04-15
EP1037991B1 (en) 2005-09-28
WO1999031241A1 (en) 1999-06-24
IL136621A0 (en) 2001-06-14
ES2251120T3 (es) 2006-04-16
US20090324597A1 (en) 2009-12-31
JP2002508183A (ja) 2002-03-19
US7193058B2 (en) 2007-03-20
IL136621A (en) 2008-07-08
DE69831754T2 (de) 2006-06-29
US7807796B2 (en) 2010-10-05
US6774224B2 (en) 2004-08-10
ATE305510T1 (de) 2005-10-15
DK1037991T3 (da) 2006-01-09
US7427669B2 (en) 2008-09-23
US20030147847A1 (en) 2003-08-07
US6458350B1 (en) 2002-10-01
US8410252B2 (en) 2013-04-02
US20080008715A1 (en) 2008-01-10
US20110281789A1 (en) 2011-11-17
DE69831754D1 (de) 2006-02-09
AU742757C (en) 2007-05-17

Similar Documents

Publication Publication Date Title
AU742757B2 (en) Cell surface glycoproteins associated with human B cell lymphomas - ULBP, DNA and polypeptides
EP1049777B1 (en) Acpl dna and polypeptides
US7767793B2 (en) Antibodies to SIGIRR
AU2255397A (en) Receptor protein designated 2f1
WO1999035267A1 (en) Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
AU759375B2 (en) IL-1 delta DNA and polypeptides
US20080081043A1 (en) NK cell activation inducing ligand (NAIL) DNA and polypeptides, and use thereof
WO1999031256A2 (en) Cathepsin dc proteins, dna encoding the proteins, and their use in human cancer prognosis
AU753195B2 (en) TIGIRR DNA and polypeptides

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued